EUROBIO SCIENTIFIC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.28 EUR | -1.11% |
|
-4.16% | -13.24% |
| 11/04 | Eurobio Scientific: 2023 results down, share price falls | CF |
| 30/01 | Eurobio Scientific Société anonyme acquired Alpha Biotech Ltd. | CI |
| Sales 2023 * | 131M 140M 11.65B | Sales 2024 * | 138M 148M 12.31B | Capitalization | 146M 156M 13.02B |
|---|---|---|---|---|---|
| Net income 2023 * | 6M 6.42M 535M | Net income 2024 * | 9M 9.62M 803M | EV / Sales 2023 * | 1.19 x |
| Net Debt 2023 * | 8.8M 9.41M 785M | Net cash position 2024 * | 9.9M 10.59M 883M | EV / Sales 2024 * | 0.99 x |
| P/E ratio 2023 * |
33.2
x | P/E ratio 2024 * |
15
x | Employees | 304 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 59.14% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.11% | ||
| 1 week | -4.16% | ||
| Current month | -11.30% | ||
| 1 month | -11.30% | ||
| 3 months | -7.99% | ||
| 6 months | -8.93% | ||
| Current year | -13.24% |
1 week
14.10
14.80
1 month
14.1016.48
Current year
14.1018.10
1 year
12.2018.10
3 years
12.2029.76
5 years
3.0829.76
10 years
2.9229.76
| Managers | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/17/19 |
| Director of Finance/CFO | 43 | 01/22/01 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/17/19 |
| Director/Board Member | 68 | 04/09/04 | |
| Director/Board Member | 67 | 15/17/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 14.28 | -1.11% | 1,639 |
| 25/24/25 | 14.44 | -0.14% | 2,718 |
| 24/24/24 | 14.46 | +0.28% | 1,526 |
| 23/24/23 | 14.42 | -2.57% | 1,051 |
| 22/24/22 | 14.8 | -0.67% | 5,724 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The group has approximately 286 employees, three production units based in the Paris region, in Germany and in the United States, and subsidiaries in Dorking in the United Kingdom, Sissach in Switzerland, Bünde in Germany and Utrecht in the Netherlands.
Calendar
13/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.28
EUR
Average target price
30
EUR
Spread / Average Target
+110.08%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.24% | 156M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ALERS Stock
